Table 4. Genes we prioritised as drug targets that had MR and colocalization evidence with other indications.
Gene expression-disease relationship identified in the main MR (instrument-gene-indication): Alzheimer’s disease (AD), Schizophrenia (Sz), anorexia (AN), suggested direction of drug action according to MR effect (inhibition or promotion of gene expression), other indications detected with the same gene in our MR-PheWAS (other indication), Wald ratio (WR), SE and P-value of MR effect and colocalization probability PP4 (coloc).
| instrument-gene-indication | drug mechanism | other indication | WR | SE | P | coloc |
|---|---|---|---|---|---|---|
| rs4295-ACE-AD | promotion (negative MR effect) | Non-cancer illness code self-reported: hypertension | 0.024 | 0.003 | 3.57x10-15 | 99.0 |
| rs2708630-RERE-Sz | inhibition (positive MR effect) | Heel bone mineral density (BMD) T-score automated | -0.080 | 0.010 | 2.17x10-16 | 97.1 |
| Diastolic blood pressure automated reading | 0.054 | 0.008 | 2.15x10-12 | 96.6 | ||
| Systolic blood pressure automated reading | 0.050 | 0.008 | 1.58x10-10 | 96.7 | ||
| Age at menarche | 0.081 | 0.021 | 1.50x10-4 | 97.8 | ||
| rs1081975-SUOX-AN | promotion (negative MR effect) | Non-cancer illness code self-reported: hypothyroidism/myxoedema | -0.008 | 0.001 | 1.20x10-10 | 87.0 |
| Rheumatoid arthritis | 0.199 | 0.033 | 2.23x10-9 | 97.9 | ||
| Non-cancer illness code self-reported: hypertension | 0.011 | 0.003 | 3.06x10-5 | 74.9 |